Clinical Trials Logo

Erosive Esophagitis clinical trials

View clinical trials related to Erosive Esophagitis.

Filter by:

NCT ID: NCT06391177 Recruiting - Clinical trials for Helicobacter Pylori Infection

A Study to Evaluate Vonoprazan Concentrations in Breast Milk of Healthy Lactating Women Receiving Vonoprazan 20 mg Once Daily

Start date: June 3, 2024
Phase: Phase 1
Study type: Interventional

The primary objective is to determine the pharmacokinetics (PK) of vonoprazan in breast milk of healthy lactating women who have received vonoprazan administered once daily for 4 consecutive days.

NCT ID: NCT05890001 Enrolling by invitation - Erosive Esophagitis Clinical Trials

A Study to Evaluate the Long-Term Safety of BLI5100 in Patients With Gastroesophageal Reflux Disease

Start date: April 5, 2023
Phase: Phase 3
Study type: Interventional

The objective of this study is to evaluate the safety of up to 12 months (52 weeks) of once daily oral administration of BLI5100 in patients with non-erosive reflux disease (NERD) or healed erosive esophagitis (EE).

NCT ID: NCT05587309 Recruiting - Erosive Esophagitis Clinical Trials

A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Erosive Esophagitis

Start date: October 30, 2022
Phase: Phase 3
Study type: Interventional

The objective of the Healing Phase of the study is to evaluate the safety and efficacy of up to 8 weeks of once daily oral administration of BLI5100 versus a PPI control in healing EE. The objective of the Maintenance Phase of the study is to evaluate the safety and efficacy of 24 weeks of once daily oral administration of BLI5100 (low or high dose) versus a PPI control in the maintenance of healed EE.

NCT ID: NCT05443984 Recruiting - Erosive Esophagitis Clinical Trials

JP-1366 20mg Versus Esomeprazole 40mg in Patients With Erosive Esophagitis

Start date: January 17, 2022
Phase: Phase 3
Study type: Interventional

To evaluate the efficacy and safety of JP-1366 20 mg compared to esomeprazole 40 mg in patients with erosive esophagitis

NCT ID: NCT05267613 Recruiting - Erosive Esophagitis Clinical Trials

Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis.

EE
Start date: July 1, 2022
Phase: Phase 3
Study type: Interventional

The aim of the study is to compare the safety and efficacy of two doses of Nexium in maintaining healing of erosive esophagitis in patients 1 to 11 years of age.

NCT ID: NCT05055128 Completed - Erosive Esophagitis Clinical Trials

A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole

Start date: August 11, 2021
Phase: Phase 2
Study type: Interventional

This study will be conducted in patients with erosive esophagitis due to gastro-esophageal reflux disease (GERD) Los Angeles (LA) grades C or D, and in patients with at least partial symptom response but still endoscopically unhealed (LA grades A or B) after 8 weeks history of standard treatment healing course with PPI, designed to support dose selection for Phase 3 and to investigate safety, tolerability, and healing rates after 4 weeks treatment of X842 or Lansoprazole, and symptom pattern during subsequent 4 weeks treatment with Lansoprazole.

NCT ID: NCT05050188 Completed - Erosive Esophagitis Clinical Trials

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics/Pharmacodynamics of Oral Doses of H008

Start date: June 24, 2021
Phase: Phase 1
Study type: Interventional

This will be a Phase I, randomized, double-blind, positive- and placebo-controlled study to evaluate the safety, tolerability, and PK/PD of multiple oral doses of H008 in healthy adult subjects. Two dose levels of H008 at 20 mg and 40 mg will be studied in two sequential cohorts. Each cohort will be enrolled with 12 subjects (8 on H008, 2 on placebo and 2 on positive control drug). Subjects are only allowed to participate in one of the two cohorts. Both the investigational product and placebo will be given in a double blinded manner, while the positive control drug will be given in an open-label manner.Dose escalation to the next cohort will be permitted only when safety data until follow-up and PK data until 48 hours post-last dose, from all subjects in previous cohorts are reviewed, and the investigational product is deemed well tolerated. The study will consist of a screening period, a baseline period, a 7-day repeated-dose period and a safety follow-up period.

NCT ID: NCT04888819 Recruiting - Erosive Esophagitis Clinical Trials

Treatment Effect According to Timing of Administration of DWP14012 40 mg

Start date: February 1, 2021
Phase: N/A
Study type: Interventional

The primary objective of this study is to establish noninferiority of efficacy of DWP14012 (40 mg once daily) based on Timing of Administration.

NCT ID: NCT04613895 Not yet recruiting - Erosive Esophagitis Clinical Trials

Treatment Effect According to Timing of Administration of DWP14012 40 mg

Start date: November 17, 2020
Phase: N/A
Study type: Interventional

The primary objective of this study is to establish noninferiority of efficacy of DWP14012 (40 mg once daily) based on Timing of Administration.

NCT ID: NCT04255693 Recruiting - Clinical trials for Gastroesophageal Reflux Disease

Real-life Study of Changes of Gastroesophageal Reflux Disease Manifestations Due to Behavioural and Diet Adherence

Start date: January 31, 2020
Phase: N/A
Study type: Interventional

This study is aimed to investigate the role of long-term diet adherence on manifestations of gastroesophageal reflux disease